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As Parkinson’s disease progresses, a massive loss of dopaminergic neurons is
accompanied by accumulation of alpha-Synuclein (αSyn) neuronal inclusions called Lewy
bodies and Lewy neurites. Inclusions first appear in olfactory bulb and enteric neurons
then in ascendant neuroanatomical interconnected areas, and finally, in late stages of the
disease, Lewy bodies are observed in a substantia nigra pars compacta with clear signs
of neuronal loss. It is believed that the spreading of Lewy bodies through the nervous
system is a consequence of the cell-to-cell propagation of αSyn, that can occur via
sequential steps of secretion and uptake. Certain pathological forms of transmitted αSyn
are able to seed endogenous counterparts in healthy recipient cells, thus promoting the
self-sustained cycle of inclusion formation, amplification and spreading, that ultimately
underlies disease progression. Here we review the cell-to-cell propagation of αSyn
focusing on its role in the progression of Parkinson’s disease.
Keywords: Parkinson’s disease, alpha-Synuclein, neurodegeneration, cell-to-cell propagation, Lewy bodies,
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ALPHA-SYNUCLEIN AND PARKINON’S DISEASE
Parkinson’s disease (PD) is a complex degenerative disorder that is pathologically characterized
by a massive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and the
progressive accumulation of Lewy bodies and Lewy neurites (LBs/LNs), two forms of inclusions rich
in filaments of aggregated alpha-Synuclein (αSyn) (Spillantini et al., 1997). Although a causative
role remains to be formally established, the facts that LBs/LNs are present in virtually all sporadic
and familial forms of PD (Poulopoulos et al., 2012), that point mutations and multiplications
of the αSyn-encoding gene, SNCA, lead to early onset PD (Polymeropoulos et al., 1997; Krüger
et al., 1998; Singleton et al., 2003; Chartier-Harlin et al., 2004; Zarranz et al., 2004) and that SNCA
polymorphisms positively correlate with PD risk (Satake et al., 2009; Simón-Sánchez et al., 2009;
Edwards et al., 2010) attest an irrefutable link between PD and αSyn.
Since the discovery that αSyn is abundant in LBs in the late 90s, a tremendous effort has been
made to determine the precise 3D conformations adopted by this protein under physiological
conditions. It is clear now that in aqueous solution αSyn behaves as an intrinsically disordered
protein, lacking a defined or stable structure (Uversky and Eliezer, 2009; Drescher et al., 2012).
Although still a matter of extensive debate, an emerging consensus indicates that within healthy
cells αSyn exists as soluble low molecular weight species that play important roles in intra and
extracellular vesicle trafficking and dynamics (Burre et al., 2010; Bartels et al., 2011; Fauvet et al.,
2012; Theillet et al., 2016). In disease-related contexts, however, αSyn is also found as β-sheet-
enriched amyloid aggregates that reside within and constitute the building blocks of LBs/LNs
(Spillantini et al., 1997; Baba et al., 1998; Conway et al., 1998, 2000). Compelling evidence indicates
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that the culprits of toxicity are oligomers and higher order
assemblies of αSyn such as amyloid fibrils (El-Agnaf et al., 1998;
Winner et al., 2011; Rockenstein et al., 2014).
THE CELL-TO-CELL TRANSMISSION OF
αSYN
Early neuroanatomical studies conducted mainly by Braak
and co-workers revealed that LBs appear first in the olfactory
bulb and enteric neurons and that only after several years they
are found in certain areas of the midbrain such as SNpc and
eventually neocortex (Wakabayashi et al., 1988; Braak et al.,
2003a, 2006; Braak and Del Tredici, 2008). Thus, during the
progression of the disease, LBs are found in a stereotypical and
topographical distribution in the nervous system. This highly
predictable pattern of LB distribution was not taken into deep
consideration until the subsequent discovery (in 2008) that
healthy neurons would acquire LBs when grafted into the brains
of PD patients (Kordower et al., 2008a,b; Li et al., 2008, 2010). A
few years later, the demonstration that αSyn is transmitted from
cell-to-cell led to the unifying hypothesis that the transcellular
FIGURE 1 | Hypothetical model of α-Synuclein cell-to-cell transmission. In pathological conditions, αSyn is found as β-sheet-enriched amyloid aggregates and
fibrils that reside within Lewy bodies and Lewy neurites (LBs/LNs). Neurons containing LBs (left) could release αSyn aggregates and seeds into the extracellular milieu
by different mechanisms such as non-classical exocytosis or via exosomes (1). Extracellular αSyn is then internalized by endocytosis by neighbor neurons as well as
glial cells (2). Due to its amyloidogenic nature, uptake of exogenous seeds promotes the structural corruption of endogenous counterpart in healthy recipient neuronal
cells (right). Thus, monomers of the recipient cell are converted into aggregates and fibrils by direct action of exogenous seeds (3) and new LBs are formed (not
shown). Neuronal viability is severely affected by two mechanisms; (i) the intrinsic cytotoxic properties of intracellular αSyn aggregates and (ii) indirectly by action of
proinflammatory molecules released by glial cells activated upon exposure to extracellular αSyn seeds (4).
transmission of certain forms of αSyn underlies LB pathogenesis
and spreading, and by extension, PD progression (Dunning
et al., 2012). This hypothesis was originally supported by clinical
evidence suggesting “host-to-graft” transmission of pathological
αSyn forms: when embryonic mesencephalic neurons were
grafted into PD patient’s brains, they developed LBs several years
after grafting (Kordower et al., 2008a,b; Li et al., 2008, 2010). The
in vitro evidence supporting the cell-to-cell propagation of αSyn
is its release by unconventional secretion (Emmanouilidou et al.,
2010) and the uptake of extracellular αSyn (both natural and
recombinant forms) by active mechanisms involving endocytosis
(Figure 1; Sung et al., 2001; Liu et al., 2007; Lee et al., 2008a).
αSyn can also be transmitted trans-synaptically and through
tunnel-like structures that connect the cytosol of neighbor cells
(Danzer et al., 2011; Abounit et al., 2016). In vivo evidence
includes the slow but persistent acquisition of LB-like inclusions
by healthy neuronal cells that have been grafted into the brains
of mice predisposed to develop LB-pathology spontaneously,
such as αSyn transgenic mice (Desplats et al., 2009; Hansen
et al., 2011). Similarly, an early onset and widespread LB-
like pathology is observed in animals that had received
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an intracerebral dose of brain homogenates of diseased αSyn
transgenic mice (Luk et al., 2012b). While other factors present in
brain homogenates could be involved, αSyn alone is sufficient to
initiate LB-like pathology and its subsequent spreading: a single
intracerebral injection of synthetic αSyn preformed fibrils leads
to pathogenesis and progressive accumulation LB-like inclusions
in neuroanatomically-interconnected areas accompanied
by pathological features of PD such as neurodegeneration,
neuroinflammation and motor deficits (Luk et al., 2012a; Sacino
et al., 2014). This induction of LB-like pathology by intracerebral
administration of αSyn aggregates strictly depends on the
presence of αSyn in the host recipient cell, as no pathology can
be induced in αSyn knock out mice (Luk et al., 2012b; Mougenot
et al., 2012). The requirement of endogenous αSyn on LB-like
inclusion spreading is explained by the observation in cell
cultures that upon uptake, preformed αSyn fibrils promote the
structural corruption of endogenous αSyn and its recruitment
into newly formed inclusions (Luk et al., 2009; Waxman and
Giasson, 2010; Volpicelli-Daley et al., 2011, 2014). Thus, host
αSyn would be essential for the amplification of inclusions, an
idea that needs to be further challenged (Helwig et al., 2016).
Recruitment of host αSyn by exogenous αSyn has also been
demonstrated in vivo in most mouse models in which LB
pathogenesis is induced by administration of exogenous αSyn
seeds (Luk et al., 2012b).
BRAAK’S HYPOTHESIS IN PD
PROGRESSION
Braak and colleagues discovered that in sporadic PD, Lewy
body pathology is first observed in the lower brainstem and
anterior olfactory structures and that it then ascends following
a caudo-rostral pattern from the dorsal motor nucleus through
susceptible areas of the medulla, pontine tegmentum, midbrain,
basal forebrain, reaching in some extreme cases the cerebral
cortex (Braak et al., 2003a). These observations elegantly detailed
LB spreading along the central nervous system (CNS), but they
did not explain where and how the inclusions are originated.
Thus, the provocative idea that LB-pathology begins when
a neurotropic pathogen enters the nervous system and then
spreads in a retrograde-axonal and transneuronal manner from
one vulnerable brain region to the next was then introduced
(Braak et al., 2003b; Hawkes et al., 2007). While in transit, this
pathogen induces formation of αSyn-positive inclusions in these
traceable CNS areas. It is now evident that certain species of αSyn
can fulfill the requirements for Braak’s neurotropic pathogen, and
that both the olfactory and gastric tracks are largely compatible
with the putative entry routes. In support of this, LB pathology is
found in both the anterior olfactory nucleus as well as olfactory
bulb mitral cells, the projection neurons that receive inputs from
the olfactory epithelium (Daniel and Hawkes, 1992; Braak et al.,
2003a). LB pathology has long been known to occur in the
gastrointestinal tract of PD patients and is well documented in all
the stages of PD (Braak et al., 2006; Lebouvier et al., 2008; Pouclet
et al., 2012). Importantly, Braak and colleagues also provided the
explanation for the observed non-random distribution of LBs
along the nervous system by showing that different cell types have
different susceptibilities to the development of inclusions. They
concluded that neurons with a long, thin and poorly myelinated
axon are highly susceptible to develop inclusions (Braak and
Braak, 2000; Braak et al., 2003b). Importantly, these features
are found in the enteric vagal preganglionic neurons that are
susceptible to developing LB-pathology in early asymptomatic
stages of the disease (Braak and Del Tredici, 2004).
MECHANISMS OF TOXICITY
Like many aspects of its intercellular transmission, very little
is known on the mechanisms of toxicity inherent to cell-
to-cell transmitted αSyn. Likewise, how αSyn transmission
is modulated or whether PD-related familial mutations or
somatic copy number variations of the SNCA gene influence
αSyn transmission remains to be determined. Taking into
consideration our current knowledge on the consequences of
αSyn misregulation, it is conceivable that cell-to-cell transmitted
and endogenous αSyn share cytotoxic mechanisms that directly
impact neuronal survival. These include, but are not limited
to, the loss of function of endogenous αSyn as a consequence
of its seeded aggregation, a phenomenon that massively affects
neuronal physiological processes such as vesicle trafficking
including neurotransmitter release and recycling (Jenco et al.,
1998; Abeliovich et al., 2000; Murphy et al., 2000; Cabin et al.,
2002; Chandra et al., 2005), the impairment of mitochondrial
activity that perturbs not only a plethora of metabolic processes
but also degradative pathways (Martin et al., 2006; Devi et al.,
2008; Liu et al., 2009; Chinta et al., 2010; Loeb et al., 2010), and
the disruption of vesicular transport mechanisms, in particular
those that trigger endoplasmic reticulum stress (Cooper et al.,
2006; Gitler et al., 2008; Thayanidhi et al., 2010). However, it
is still possible that cell-to-cell transmitted αSyn has its own
particular repertoire of cytotoxic properties, in addition to its
probable distinct physiological functions. The fact that cell-
to-cell transmitted αSyn is released to the extracellular milieu
allowed neuroscientists to develop cellular and animal models
based in administration of exogenous αSyn species that would
recapitulate key mechanistic aspects of αSyn transmission such
as its internalization and downstream events. Data obtained from
glial cells might constitute the first evidence that endogenous
and exogenously acquired αSyn might behave differently. It
is well known that glial cells normally do not express αSyn
mRNA (Reyes et al., 2014) and instead acquire the protein
from the extracellular milieu (Liu et al., 2007; Lee et al.,
2008b, 2010; Park et al., 2009). Thus, uptake of exogenous
αSyn not only would explain the source of αSyn in glial
cytoplasmic inclusions (GCIs) inmultiple system atrophy (MSA),
a progressive neurodegenerative disease related to PD and other
synucleinopaties (Tu et al., 1998), but also would uncover a
unique role for extracellular αSyn in the context of αSyn-deficient
cells. Furthermore, it was shown that extracellular αSyn activates
astrocytes and microglia in vitro and in vivo resulting in a
neuroinflammatory response reminiscent to that observed in
PD (Zhang et al., 2005; Lee et al., 2010; Alvarez-Erviti et al.,
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2011; Halliday and Stevens, 2011; Luk et al., 2012a). Noteworthy,
neurons are highly susceptible to glial-derived proinflammatory
factors, therefore representing an alternative neurotoxic process
triggered specifically by cells that have acquired αSyn from
the extracellular milieu. Although the neuron-glia interaction
might help to elucidate specific and non-redundant roles for
intracellular and extracellular cell-to-cell transmitted αSyn, the
molecular and biochemical determinants that presumably make
these two forms of αSyn different remain completely unexplored.
THE PRION HYPOTHESIS
As a consequence of Braak’s model formulation, the idea that
PD behaves as a prion disease has emerged, leading some to
refer to it as a “prion-like” disorder. Of note, unlike prions,
transmissibility between individuals of pathological forms of
αSyn has not been demonstrated and thereby αSyn is currently
considered as a non-infectious protein (Aguzzi and Rajendran,
2009; Beekes et al., 2014). The analogy to prion diseases stems
for the fact that in in vivo experiments, involving mostly
rodents and in some cases non-human primates, intracerebral
administration of exogenous αSyn (either αSyn-containing brain
material or synthetic αSyn proteins) is sufficient to trigger
LB pathogenesis, amplification and spreading. These processes
are usually accompanied by the phenotypic changes naturally
observed in PD such as neurodegeneration, neuroinflammation,
and motor deficits. Furthermore, it has been shown that in some
cases the particular structural conformation of the exogenous
αSyn seed, normally referred to as the “conformational strain”,
is transmitted from the exogenously administered aggregates to
host αSyn and thereby to the newly formed inclusions (Bousset
et al., 2013; Guo et al., 2013; Peelaerts et al., 2015). This supports
the idea of that the applied exogenous αSyn acts as seeds that
template the aggregation of homotypic molecules of the host,
a phenomenon characteristic of prions. The evidence of PD as
a prion-like disorder is accumulating, however, there are still
several unsolved questions that should be addressed before this
terminology is broadly accepted. These questions arise from the
inherent limitations of animal models for the full recapitulation
of the human condition. In this sense, a constantly growing
effort is being made to better characterize the brain material
that contains neurotoxic αSyn species and the synthetic αSyn
aggregates that are administrated intracerebrally to trigger PD-
like pathology (Bousset et al., 2013; Tuttle et al., 2016). To
uncover the molecular similarities and differences between the
αSyn used in such in vivo experiments and those contained in
Lewy bodies and Lewy neurites is critical to comprehensively
understand the scopes and limitations of such animal models
and the resultant hypotheses. As an example of such a gap of
information, it has long been reported that certain forms of
αSyn are found in the cerebrospinal fluid (CSF) of both healthy
subjects and PD patients (Borghi et al., 2000; Tokuda et al., 2006;
Mollenhauer et al., 2010; Parnetti et al., 2011; Foulds et al., 2012).
However, it remains an enigma which structural species of αSyn
are found in CSF and whether these molecules correspond to
the transmitted species that mediate the pathogenic process that
underlies LB pathogenesis and spreading. Elucidating this will
help to reconcile clinical evidence arguing against the concept
of prion-like progression in Parkinson’s disease and related
synucleinopaties (Hallett et al., 2014).
CONCLUDING REMARKS
The discovery of the cell-to-cell propagation of αSyn and
in particular its role as mediator of disease progression has
opened new therapeutic avenues for the treatment of PD and
related neurological disorders, and novel therapies targeting
extracellular αSyn aimed to delay or stop disease progression are
currently being explored. The therapeutic potential of passive
immunotherapy targeting aberrant forms of αSyn, for instance,
has recently been investigated showing that it efficiently interferes
with uptake of extracellular αSyn seeds preventing downstream
effects such as amplification and transmission of pathological
aggregates (Tran et al., 2014). Similarly, administration of
rationally engineered antibodies robustly promotes degradation
and neutralization of internalized αSyn preventing cell-to-cell
aggregate transmission and neuronal loss (Bae et al., 2012;
Spencer et al., 2014). Nevertheless, the elucidation of the
mechanisms involved in αSyn transcellular transmission will be
instrumental not only for the development of novel therapies
for PD but also for the understanding of the “prion-like”
properties of amyloid-beta (Aβ), tau and Huntingtin, all of them
transmissible aggregation-prone proteins with a long history in
neurodegenerative diseases such as Alzheimer and Huntington’s
diseases, respectively (Brettschneider et al., 2015).
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